Physician profile
Lisa Whitcomb
NPI 1508977695
$1,801.78
in general payments reported to CMS, 2019-2025
25 companies · $260 in 2025
The $260 reported for 2025 was more than what 81% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $102 · 2021: $274 · 2022: $408 · 2023: $301 · 2024: $190 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $750.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $715.43 | 2021-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $177.11 | 2019-2024 | Bexsero |
| Sanofi Pasteur INC. | $157.06 | 2022-2025 | |
| Neos Therapeutics, LP | $126.71 | 2020-2022 | |
| Pfizer INC. | $107.84 | 2019-2023 | |
| Ironshore Pharmaceuticals INC. | $61.21 | 2019-2020 | |
| Abbvie INC. | $51.13 | 2022-2023 | Liletta |
| Hologic Sales and Service, LLC | $39.40 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Seqirus USA INC | $34.61 | 2025 | Flucelvax |
| Ultragenyx Pharmaceutical INC. | $34.09 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.77 | 2019-2022 | |
| Coopersurgical, INC. | $32.56 | 2025 | Paragard T 380a |
| Genentech USA, INC. | $26.02 | 2019-2020 | |
| Corium, LLC | $25.65 | 2025 | Azstarys |
| Sanofi-Aventis U.S. LLC | $20.80 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $20.13 | 2025 | Zurzuvae |
| Biomarin Pharmaceutical INC. | $19.13 | 2025 | Voxzogo 1.2mg |
| Merck Sharp & Dohme LLC | $18.48 | 2025 | Gardasil 9, Rotateq, Enflonsia |
| Novo Nordisk INC | $16.35 | 2024 | Wegovy |
| Alk-Abello, INC | $15.00 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $14.86 | 2025 | Neffy |
| Dermira, INC. | $14.84 | 2020 | |
| Mylan Pharmaceuticals INC. | $14.03 | 2019 | |
| Adlon Therapeutics L.P. | $14.01 | 2021 | |
| Shire North American Group INC | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Whitcomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.